Promoter hypermethylation of resected bronchial margins: A field defect of changes?

Clinical Cancer Research

Volumn 10, Issue 15, 2004, Pages 5131-5136

  Guo, Mingzhou ^a   House, Michael G ^a   Hooker, Craig ^a   Han, Yu ^a   Heath, Elizabeth ^a   Gabrielson, Edward ^a   Yang, Stephen C ^a   Baylin, Stephen B ^a   Herman, James G ^a   Brock, Malcolm V ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; DEATH ASSOCIATED PROTEIN KINASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P16; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOIC ACID RECEPTOR BETA; SUPPRESSOR OF CYTOKINE SIGNALING 1;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; DNA METHYLATION; HUMAN; HUMAN TISSUE; LUNG CARCINOGENESIS; LUNG LAVAGE; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; METASTASIS; POLYMERASE CHAIN REACTION; PRECANCER; PRIORITY JOURNAL; PROMOTER REGION;

ADULT; AGED; AGED, 80 AND OVER; BRONCHI; BRONCHOALVEOLAR LAVAGE FLUID; CARCINOMA, NON-SMALL-CELL LUNG; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA; DNA METHYLATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); RECURRENCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 4143132121     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-03-0763     Document Type: Article

References (32)

1. Kulka F, Kostic S. Surgical alternatives in ipsilateral recurrence of bronchogenic carcinoma. Eur J Cardiothorac Surg 1988;2:430-2.
2. Hofmann HS, Taege C, Lautenschlager C, et al. Microscopic (R1) and macroscopic (R2) residual disease in patients with resected non-small cell lung cancer. Eur J Cardiothorac Surg 2002;21:606-10.
3. Shields TW. The fate of patients after incomplete resection of bronchial carcinoma. Surg Gynecol Obstet 1974;139:569-72.
4. Soorae AS, Stevenson HM. Survival with residual tumor on the bronchial margin after resection for bronchogenic carcinoma. J Thorac Cardiovasc Surg 1979;78:175-80.
5. Lequaglie C, Conti B, Brega Massone PP, Giudice G. Unsuspected residual disease at the resection margin after surgery for lung cancer: fate of patients after long-term follow-up. Eur J Cardiothorac Surg 2003;23:229-32.
6. Law MR, Hodson ME, Lennox SC. Implications of histologically reported residual tumour on the bronchial margin after resection for bronchial carcinoma. Thorax 1982;37:492-5.
7. Gephardt GN, Baker PB. Lung carcinoma surgical pathology report adequacy: a College of American Pathologists Q-Probes study of over 8300 cases from 464 institutions. Arch Pathol Lab Med 1996;120: 922-7.
8. Kaiser LR, Fleshner P, Keller S, Martini N. Significance of extramucosal residual tumor at the bronchial resection margin. Ann Thorac Surg 1989;47:265-9.
9. Ghiribelli C, Voltolini L, Paladini P, et al. Treatment and survival after lung resection for non-small cell lung cancer in patients with microscopic residual disease at the bronchial stump. Eur J Cardiothorac Surg 1999;16:555-9.
10. Kayser K, Anyanwu E, Bauer HG, Vogt-Moykopf I. Tumor presence at resection boundaries and lymph-node metastasis in bronchial carcinoma patients. Thorac Cardiovasc Surg 1993;41:308-11.
11. Lacasse Y, Bucher HC, Wong E, et al. "Incomplete resection" in non-small cell lung cancer: need for a new definition. Canadian Lung Oncology Group. Ann Thorac Surg 1998;65:220-6.
12. Liewald F, Hatz RA, Dienemann H, Sunder-Plassmann L. Importance of microscopic residual disease at the bronchial margin after resection for non-small-cell carcinoma of the lung. J Thorac Cardiovasc Surg 1992;104:408-12.
13. Dienemann H, Trainer C, Hoffmann H, et al. Incomplete resections in bronchial carcinoma: morbidity and prognosis [in German]. Chirurg 1997;68:1014-9.
14. Gebitekin C, Gupta NK, Satur CM, et al. Fate of patients with residual tumour at the bronchial resection margin. Eur J Cardiothorac Surg 1994;8:339-42, discussion 342-4.
15. Passlick B, Sitar I, Sienel W, et al. Significance of lymphangiosis carcinomatosa at the bronchial resection margin in patients with non-small cell lung cancer. Ann Thorac Surg 2001;72:1160-4.
16. Esteller M, Fraga MF, Paz MF, et al. Cancer epigenetics and methylation. Science (Wash DC) 2002;297:1807-8, discussion 1807-8.
17. Esteller M, Com PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001;61:3225-9.
18. Esteller M, Sanchez-Cespedes M, Rosell R, et al. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999;59:67-70.
19. Ahrendt SA, Chow JT, Xu LH, et al. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst (Bethesda) 1999;91:332-9.
20. Belinsky SA, Palmisano WA, Gilliland FD, et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 2002;62:2370-7.
21. Ng CS, Zhang J, Wan S, et al. Tumor p16M is a possible marker of advanced stage in non-small cell lung cancer. J Surg Oncol 2002;79: 101-6.
22. 0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1995;60:615-22, discussion 622-3.
23. Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821-6.
24. van Engeland M, Weijenberg MP, Roemen GM, et al. Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer. Cancer Res 2003;63:3133-7.
25. Toyota M, Shen L, Ohe-Toyota M, et al. Aberrant methylation of the cyclooxygenase 2 CpG island in colorectal tumors. Cancer Res 2000;60:4044-8.
26. Yoshikawa H, Matsubara K, Qian GS, et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 2001;28:29-35.
27. Yang B, Guo M, Herman JG, Clark DP. Aberrant promoter methylation profiles of tumor suppressor genes in hepatocellular carcinoma. Am J Pathol 2003;163:1101-7.
28. van Engeland M, Roemen GM, Brink M, et al. K-ras mutations and RASSF1A promoter methylation in colorectal cancer. Oncogene 2002; 21:3792-5.
29. INK4a in primary rat lung tumors. Mol Cell Biol 1997;17:1366-74.
30. Andre F, Grunenwald D, Pujol JL, et al. Patterns of relapse of N2 non-small-cell lung carcinoma patients treated with preoperative chemotherapy: should prophylactic cranial irradiation be reconsidered? Cancer (Phila) 2001;91:2394-400.
31. Zochbauer-Muller S, Lam S, Toyooka S, et al. Aberrant methylation of multiple genes in the upper aerodigestive tract epithelium of heavy smokers. Int J Cancer 2003;107:612-6.
32. Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics 1989;45:255-68.